Frédéric Lirussi

Prof. Frédéric Lirussi

orcid

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 November 2015 in JNCI: Journal of the National Cancer Institute
Verified
Journal Article
Closed access
PDF file
JGJessica Gobbo
Jessica Gobbo
GMGuillaume Marcion
Guillaume Marcion
MCMarine Cordonnier
Marine Cordonnier
ADAlexandre M. M. Dias
Alexandre M. M. Dias
NPNicolas Pernet
Nicolas Pernet
GCGarrido Carmen
Garrido Carmen
Background: Exosomes, via heat shock protein 70 (HSP70) expressed in their membrane, are able to interact with the toll-like receptor 2 (TLR2) on myeloid-derived suppressive cells (MDSCs), thereby activating them. Methods: We analyzed exosomes from mouse (C57Bl/6) and breast, lung, and ovarian cancer patient samples and cultured cancer cells with different approaches, including nanoparticle tracking analysis, biolayer interferometry, FACS, and electron microscopy. Data were analyzed with the Student’s t and Mann-Whitney tests. All statistical tests were two-sided. Results: We showed that the A8 peptide aptamer binds to the extracellular domain of membrane HSP70 and used the aptamer to capture HSP70 exosomes from cancer patient samples. The number of HSP70 exosomes was higher in cancer patients than in healthy donors (mean, ng/mL ± SD = 3.5±1.7 vs 0.17±0.11, respectively, P = .004). Accordingly, all cancer cell lines examined abundantly released HSP70 exosomes, whereas “normal” cells did not. HSP70 had higher affinity for A8 than for TLR2; thus, A8 blocked HSP70/TLR2 association and the ability of tumor-derived exosomes to activate MDSCs. Treatment of tumor-bearing C57Bl/6 mice with A8 induced a decrease in the number of MDSCs in the spleen and inhibited tumor progression (n = 6 mice per group). Chemotherapeutic agents such as cisplatin or 5FU increase the amount of HSP70 exosomes, favoring the activation of MDSCs and hampering the development of an antitumor immune response. In contrast, this MDSC activation was not observed if cisplatin or 5FU was combined with A8. As a result, the antitumor effect of the drugs was strongly potentiated. Conclusions: A8 might be useful for quantifying tumor-derived exosomes and for cancer therapy through MDSC inhibition.

10 February 2021 in Expert Opinion on Therapeutic Patents
Verified
Journal Article
Closed access
SHSuwen Hu
Suwen Hu
ZHZi Hui
Zi Hui
FLFrédéric Lirussi
Frédéric Lirussi
GCGarrido Carmen
Garrido Carmen
XYXiang-Yang Ye
Xiang-Yang Ye
TXTian Xie
Tian Xie
Introduction: DNA-dependent protein kinase (DNA-PK) plays a crucial role in the repair of DSBs via non-homologous end joining (NHEJ). Several DNA-PK inhibitors are being investigated for potential anticancer treatment in clinical trials. Area covered: This review aims to give an overview of patents published since 2010 by analyzing the patent space and structure features of scaffolds used in those patents. It also discusses the recent clinical developments and provides perspectives on future challenges and directions in this field. Expert opinion: As a key component of the DNA damage response (DDR) pathway, DNA-PK appears to be a viable drug target for anticancer therapy. The clinical investigation of a DNA-PK inhibitor employs both a monotherapy and a combination strategy. In the combination strategy, a DNA-PK inhibitor is typically combined with a DSB inducer, radiation, a chemotherapy agent, or a PARP inhibitor, etc. Patent analyses suggest that diverse structures comprising different scaffolds from mono-heteroaryl to bicyclic heteroaryl to tricyclic heteroaryl are capable to achieve good DNA-PK inhibitory activity and good DNA-PK selectivity over other closely related enzymes. Several DNA-PK inhibitors are currently being evaluated in clinics, with the hope to get approval in the near future.

1 August 2006 in Naunyn-Schmiedeberg's Archives of Pharmacology
Verified
Journal Article
Closed access
PDF file
PGPascal Guerard
Pascal Guerard
ZRZo Rakotoniaina
Zo Rakotoniaina
FGFrançoise Goirand
Françoise Goirand
LRLuc Rochette
Luc Rochette
MDMonique Dumas
Monique Dumas
MBMarc Bardou
Marc Bardou

15 June 2021 in Nature Communications
Verified
Journal Article
Open access
PDF file
BUBurhan Uyanik
Burhan Uyanik
AGAnastasia R. Goloudina
Anastasia R. Goloudina
AAAamir Akbarali
Aamir Akbarali
BGBogdan B. Grigorash
Bogdan B. Grigorash
APAlexey V. Petukhov
Alexey V. Petukhov
Oleg DemidovOleg Demidov
Oleg Demidov
PPM1D/Wip1 is a negative regulator of the tumor suppressor p53 and is overexpressed in several human solid tumors. Recent reports associate gain-of-function mutations of PPM1D in immune cells with worse outcomes for several human cancers. Here we show that mice with genetic knockout of Ppm1d or with conditional knockout of Ppm1d in the hematopoietic system, in myeloid cells, or in neutrophils all display significantly reduced growth of syngeneic melanoma or lung carcinoma tumors. Ppm1d knockout neutrophils infiltrate tumors extensively. Chemical inhibition of Wip1 in human or mouse neutrophils increases anti-tumor phenotypes, p53-dependent expression of co-stimulatory ligands, and proliferation of co-cultured cytotoxic T cells. These results suggest that inhibition of Wip1 in neutrophils enhances immune anti-tumor responses.

2 November 2022 in Biomedicines
Verified
Journal Article
Open access
PDF file
TLTatiana Lopez
Tatiana Lopez
MWMaeva Wendremaire
Maeva Wendremaire
JLJimmy Lagarde
Jimmy Lagarde
ODOriane DUQUET
Oriane DUQUET
LALine Alibert
Line Alibert
FLFrédéric Lirussi
Frédéric Lirussi
Many signaling pathways, molecular and cellular actors which are critical for wound healing have been implicated in cancer metastasis. These two conditions are a complex succession of cellular biological events and accurate regulation of these events is essential. Apart from inflammation, macrophages-released ROS arise as major regulators of these processes. But, whatever the pathology concerned, oxidative stress is a complicated phenomenon to control and requires a finely tuned balance over the different stages and responding cells. This review provides an overview of the pivotal role of oxidative stress in both wound healing and metastasis, encompassing the contribution of macrophages. Indeed, macrophages are major ROS producers but also appear as their targets since ROS interfere with their differentiation and function. Elucidating ROS functions in wound healing and metastatic spread may allow the development of innovative therapeutic strategies involving redox modulators.

11 November 2006 in Naunyn-Schmiedeberg's Archives of Pharmacology
Verified
Journal Article
Closed access
PDF file
ZRZo Rakotoniaina
Zo Rakotoniaina
PGPascal Guerard
Pascal Guerard
FLFrédéric Lirussi
Frédéric Lirussi
FGFrançoise Goirand
Françoise Goirand
LRLuc Rochette
Luc Rochette
MBMarc Bardou
Marc Bardou